taba - In conclusion and IMO we will be looking at two very different interested parties for these Epigenetic gems.

This could be very true. We know the science in Apabetalone has many positive attributes and may have a significant impact on revenue on some BP's.  If you were the CEO of one of those, how would you protect your revenue?  Thinking buy your competitor, RVX.  Very cheap at this time.  Most new drugs are very expensive to license and produce, ABL is inexpensive to produce.  BP could easily increase both revenue and net income with ABL.  Their SP would increase while RVX seems to find a new low.  With no revenue, no product and Eversana billing (marketing what?).  RVX will not survive without a major investment and change of management.

There are issues that prevail in a purchase of RVX.  Zen is one of those.  So BP buys both and spins one to another BP.  Sounds too complicated.  No.  Happens more frequently in professional sports, major trades. 

I am guessing that BP has made a few overtures to RVX.   Response was too expensive.  Time is runnng on RVX patent, value to BP decreases.  Plus HL may be in the way too. HL may be looking to acquire full control, so why not depress the SP, another move by China.  Many would take $10 per share, very cheap for China, not HL.  Look who is behind most companies in China.  sidebar